XmAb819 Updated Aug 31
Watch the ESMO 2026 oral presentation (likely October 2026) for updated Phase 1 dose-expansion data, specifically whether the 25% ORR holds or improves in a larger cohort and whether the safety profile (primarily Grade 1-2 CRS, rash, GI events) remains manageable. The pivotal study start in 2027 is the next major milestone after that. XNCR's ~$26 stock price already reflects a mean analyst target of $29, limiting near-term upside absent a clear data beat.
- First-in-class mechanism: XmAb819 is the only ENPP3 x CD3 bispecific in clinical development, targeting an antigen highly expressed on ccRCC cells with a differentiated 2+1 format for tumor selectivity.
- Encouraging early efficacy: 25% ORR in heavily pretreated, unselected ccRCC patients at the initial dose-escalation data cut is competitive for this refractory population and met internal criteria to advance to dose expansion.
- Strong institutional support: BlackRock ($220M), PRIMECAP ($164M), RTW Investments ($109M), and RA Capital ($85M) are top holders as of Q2 2026, and multiple funds added or doubled positions in the quarter.
- Early-stage risk: XmAb819 is still in Phase 1 dose expansion, the pivotal study hasn't started yet (planned for 2027). Approval is years away and attrition risk for Phase 1 oncology assets is high.
- Safety concerns: Cytokine release syndrome (CRS), rash, and GI toxicities were the most common adverse events. While primarily Grade 1-2, CRS is a known risk for T-cell engagers and could limit dosing or require mitigation strategies.
- Competitive ccRCC landscape: Multiple approved therapies exist (TKIs, checkpoint inhibitors, HIF-2α inhibitors) and other bispecifics/T-cell engagers are in development for RCC, creating a crowded target.